Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.71 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345148 | 1.00 | AOC3 (0.71) | AOC3GPR119CTSLACACB | |
| SCHEMBL18953100 | 1.00 | AOC3 (0.71) | AOC3GPR119CTSLACACB | |
| SCHEMBL3126584 | 1.00 | AOC3 (0.71) | AOC3GPR119CTSLACACB | |
| Hydrochloric Acid SCHEMBL28559351 | 0.99 | AOC3 (0.70) | AOC3GPR119CTSLACACB | |
| Hydrochloric Acid SCHEMBL28559350 | 0.99 | AOC3 (0.70) | AOC3GPR119CTSLACACB | |
| Phosphoric Acid SCHEMBL28576808 | 0.96 | AOC3 (0.69) | AOC3GPR119CTSL | |
| Sulfuric Acid SCHEMBL28571413 | 0.96 | AOC3 (0.67) | AOC3GPR119CTSL | |
| Sulfuric Acid SCHEMBL28571415 | 0.96 | AOC3 (0.67) | AOC3GPR119CTSL | |
| Phosphoric Acid SCHEMBL28576809 | 0.96 | AOC3 (0.69) | AOC3GPR119CTSL | |
| SCHEMBL28563810 | 0.95 | AOC3 (0.66) | AOC3GPR119CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3286189-B1 | CRYSTALLINE MESYLATE SALT AS SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME INHIBITOR | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| EP-3286190-B1 | PHARMACEUTICAL SALT FORMS OF AN INHIBITOR OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10369139-B2 | Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor | Benevolentai Cambridge Limited (GB) | 2019-08-06 | — | — | US | disclosed |
| US-10316034-B2 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) | Benevolentai Cambridge Limited (GB) | 2019-06-11 | — | — | US | disclosed |
| EP-3285767-B1 | TREATMENT OF PAIN | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| WO-2016170353-A1 | TREATMENT OF PAIN | PROXIMAGEN LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170352-A1 | CRYSTALLINE COMPOUND AS SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME INHIBITOR | PROXIMAGEN LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170351-A1 | PHARMACEUTICAL SALT FORMS OF AN INHIBITOR OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) | PROXIMAGEN LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| US-20150218161-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2015-08-06 | — | — | US | disclosed |
| US-9035066-B2 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| EP-2334672-B1 | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885GPR119 2882/4885CTSL 1541/4885 |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885GPR119 2882/4885CTSL 1541/4885 |
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885GPR119 1873/4885CTSL 1492/4885 |
| US-10369139-B2 | Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor | PNPO, MAOA, AOC3 | AOC3 3/4885GPR119 1425/4885CTSL 435/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885GPR119 1118/4885CTSL 1035/4885 |
| US-20120302583-A1 | New Compounds I | SSB, NFKBIA, NOD1 | AOC3 111/4885GPR119 628/4885CTSL 1402/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885GPR119 1873/4885CTSL 1492/4885 |
| US-10316034-B2 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) | SMOX, AOC3, DAO | AOC3 2/4885GPR119 1061/4885CTSL 1257/4885 |
| US-20150218161-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885GPR119 1118/4885CTSL 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.